Benzinga

Benzinga

Benzinga

jueves, septiembre 03

Black Diamond Therapeutics Inc

BDTXNASDAQ
Trade with Public
Trade with Public
$2.14
0.104.9%
al cierre: Sep 2, 5:00 PM EST
$2.15
0.01010.47%
After hour: 6:40 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Black Diamond Therapeutic Analyst Price Targets

Wall Street analyst price targets and consensus rating for Black Diamond Therapeutic (BDTX).

Price Target Range — 11 Quarters

Analyst Consensus — 8 Analysts

7Buy
1Hold
Consensus RatingBuy# Analysts8Avg. Consensus PT$12Upside to Avg. PT+448.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Apr 29, 2026BTIGRobert BurnsPT RaiseBuy$10→$11
Mar 17, 2026WedbushRobert DriscollPT RaiseOutperform$13→$14
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $11

BTIG analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and raises the price target from $10 to $11.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Black Diamond Therapeutic, Raises Price Target to $14

Wedbush analyst Robert Driscoll maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform and raises the price target from $13 to $14.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Black Diamond Therapeutic, Lowers Price Target to $8

Piper Sandler analyst Kelsey Goodwin maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Overweight and lowers the price target from $9 to $8.
Benzinga Newsdesk

This PayPal Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Avi Kapoor

PRO
Guggenheim Downgrades Black Diamond Therapeutic to Neutral

Guggenheim analyst Brad Canino downgrades Black Diamond Therapeutic (NASDAQ:BDTX) from Buy to Neutral.
Benzinga Newsdesk

PRO
Piper Sandler Assumes Black Diamond Therapeutic at Overweight, Announces Price Target of $9

Piper Sandler analyst Kelsey Goodwin assumes Black Diamond Therapeutic (NASDAQ:BDTX) with a Overweight rating and announces Price Target of $9.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved